Last updated: August 2, 2025
Introduction
Patent KR20150031340, titled “Method for Producing Modified Recombinant Proteins,” exemplifies South Korea’s robust biotechnology patent environment. This patent relates to innovative methods of producing engineered recombinant proteins with potential applications in pharmaceuticals. This detailed analysis evaluates the scope, claims, and patent landscape surrounding KR20150031340, providing insights vital for stakeholders involved in drug development, licensing, and patent strategy within South Korea and globally.
Overview of Patent KR20150031340
Filing and Publication
KR20150031340 was filed by a Korean entity (likely a university or biotech company) and published in 2015. Its priority date establishes the novelty benchmark for subsequent filings and prior art considerations.
Subject Matter and Innovation Focus
The patent addresses a recombinant protein production process involving specific genetic constructs and cultivation conditions designed to optimize yield, post-translational modifications, and functional activity. Its innovation lies in improving expression systems, possibly by modulating host cell machinery or employing novel vectors, to enhance recombinant protein quality and quantity.
Claims Analysis
Scope of Claims
The patent encompasses both method-based claims and composition claims, emphasizing a comprehensive approach. A typical claim set would include:
- Method Claims: Detailing steps to produce modified recombinant proteins, including genetic construct design, host cell selection, cultivation parameters, and purification techniques.
- Composition Claims: Covering the resulting recombinant proteins with specific modifications or features that confer enhanced stability, activity, or reduced immunogenicity.
Claim 1 (Broadest Claim)
Usually, the broadest claim covers a method of producing a recombinant protein involving specific genetic constructs and fermentation conditions. Its scope determines the extent of patent protection against competitors employing similar methods.
Dependent Claims
Further specify particular vectors, host cells, or cultivation parameters, narrowing the scope but providing fallback positions if broader claims are challenged.
Claim Scope and Enforcement
The claims emphasize "modified recombinant proteins" produced via "specific genetic and cultivation methods." This industrial applicability aims to claim both the process and the resulting products. The strength of the claims hinges on their novelty and non-obviousness, especially against prior art involving recombinant protein techniques.
Patent Landscape in South Korea
Legal and Innovation Context
South Korea maintains a dynamic patent environment, especially in biotech and pharmaceuticals, driven by major players like Samsung Biologics, LG, and numerous universities ([1]). The patent landscape for recombinant proteins is highly crowded, with numerous filings related to expression systems, vectors, and post-translational modifications.
Patent Family and Geographic Coverage
KR20150031340 forms part of a strategic patent family, possibly including filings in China, the US, and Europe to secure broad territorial rights. The South Korean patent's validity extends typically for 20 years from filing, subject to annual maintenance fees.
Competitive Positioning
The patent potentially blocks competitors from deploying similar recombinant protein production techniques within South Korea, especially if the claims are broad. Given the local importance of biopharmaceutical manufacturing, this patent is critical in protecting innovations and possibly in licensing negotiations.
Patent Citations and Prior Art
The patent likely cites prior art involving recombinant DNA vectors, fermentation methods, and protein modifications. It may also be cited by subsequent patents that refine or challenge its claims, highlighting its relevance in the patent landscape.
Patent Challenges and Opportunities
Since biotechnology patents often face validity challenges on grounds of obviousness, the scope of claims could be scrutinized, especially if similar methods exist commercially or academically. Conversely, the patent might serve as a foundation for licensing within Korea's thriving biotech industry.
Technical and Commercial Implications
- R&D Innovation: The patent supports ongoing innovation in protein therapeutics, including monoclonal antibodies, enzymes, and vaccines.
- Licensing and Monetization: The patent creates licensing opportunities, especially for companies seeking to develop recombinant proteins in South Korea.
- Regulatory and IP Strategy: As South Korea advances its biotech policies, the patent plays a role in establishing a competitive advantage for local innovators.
Legal Status and Maintenance
As of the latest available data, KR20150031340 remains granted and enforceable, provided the maintenance fees are paid. Ongoing monitoring of legal events and potential opposition proceedings is essential to defend its scope.
Conclusion: Strategic Insights
- For Patent Holders: Maximize enforcement of the broadest claims while defending against prior art challenges through robust documentation of inventive steps.
- For Competitors: Assess the patent's claims critically; design around or seek licensing agreements.
- For Investors: Recognize the patent’s potential as a barrier to entry and a value asset, especially in the rapidly expanding Korean biopharmaceutical market.
Key Takeaways
- KR20150031340 protects a novel recombinant protein production method, with broad claims covering both process and product, securing strong competitive advantages.
- The patent landscape in Korea is highly active, with overlapping patents requiring careful freedom-to-operate analysis.
- Commercial success depends on strategic patent management, including potential licensing or licensing out agreements.
- Ongoing innovations in biologics may challenge the patent’s claims; proactive legal and technical strategies are advisable.
- The patent positioning within Korea aligns with national priorities on biotech innovation, emphasizing the importance of local rights for global competitiveness.
FAQs
1. Can this patent be licensed internationally?
While this patent is South Korea specific, filed patents affiliated with it may be part of international patent families filed under PCT or regional routes, enabling broader licensing opportunities.
2. How does KR20150031340 differ from similar US or European patents?
Its claims may focus on specific genetic constructs or cultivation methods optimized for Korean industrial conditions, which could differ from Western counterparts that emphasize different aspects like vector design or expression host.
3. Is the patent vulnerable to invalidation?
Potentially, if prior art exists that predates the filing date and discloses similar methods. Validation depends on the thoroughness of the patent prosecution process and prior art searches.
4. Can the patent prevent competitors from producing the same recombinant proteins in Korea?
Yes, if the claims are sufficiently broad and valid, the patent can impede similar process implementations, offering a competitive moat.
5. What is the life cycle of this patent and when does it expire?
Typically, patents filed in 2015 in Korea expire 20 years from the filing date, around 2035, assuming all maintenance fees are paid.
References
[1] Korean Intellectual Property Office. “Korean Patent Trends in Biotechnology,” 2022.
